BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 14668093)

  • 1. Evaluation of caspase 1 and sFas serum levels in patients with systemic sclerosis: correlation with lung dysfunction, joint and bone involvement.
    Dziankowska-Bartkowiak B; Waszczykowska E; Zalewska A; Sysa-Jedrzejowska A
    Mediators Inflamm; 2003 Dec; 12(6):339-43. PubMed ID: 14668093
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Duration of Raynaud's phenomenon is negatively correlated with serum levels of interleukin 10 (IL-10), soluble receptor of interleukin 2 (sIL2R), and sFas in systemic sclerosis patients.
    Dziankowska-Bartkowiak B; Zalewska A; Sysa-Jedrzejowska A
    Med Sci Monit; 2004 May; 10(5):CR202-8. PubMed ID: 15114270
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation of endostatin and tissue inhibitor of metalloproteinases 2 (TIMP2) serum levels with cardiovascular involvement in systemic sclerosis patients.
    Dziankowska-Bartkowiak B; Waszczykowska E; Zalewska A; Sysa-Jedrzejowska A
    Mediators Inflamm; 2005 Aug; 2005(3):144-9. PubMed ID: 16106100
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum levels of tissue inhibitor of metalloproteinases 2 in systemic sclerosis: a preliminary study.
    Dziankowska-Bartkowiak B; Waszczykowska E; Łuczyńska M; Zalewska A; Sysa-Jedrzejowska A
    Med Sci Monit; 2002 Feb; 8(2):CR108-12. PubMed ID: 11859283
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation of serum anti-DNA topoisomerase I antibody levels with disease severity and activity in systemic sclerosis.
    Hu PQ; Fertig N; Medsger TA; Wright TM
    Arthritis Rheum; 2003 May; 48(5):1363-73. PubMed ID: 12746909
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elevation of serum lymphotactin levels in patients with systemic sclerosis.
    Muroi E; Ogawa F; Shimizu K; Komura K; Hasegawa M; Fujimoto M; Sato S
    J Rheumatol; 2008 May; 35(5):834-8. PubMed ID: 18322986
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Resistance to apoptosis in circulating alpha/beta and gamma/delta T lymphocytes from patients with systemic sclerosis.
    Cipriani P; Fulminis A; Pingiotti E; Marrelli A; Liakouli V; Perricone R; Pignone A; Matucci-Cerinic M; Giacomelli R
    J Rheumatol; 2006 Oct; 33(10):2003-14. PubMed ID: 17014016
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elevated levels of serum soluble Fas are associated with organ and tissue damage in systemic lupus erythematosus among Chinese.
    Hao JH; Ye DQ; Zhang GQ; Liu HH; Dai H; Huang F; Pan FM; Su H; Dong MX; Chen H; Wang Q; Zhang XJ
    Arch Dermatol Res; 2006 Jan; 297(7):329-32. PubMed ID: 16328345
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum CXCL16 concentrations correlate with the extent of skin sclerosis in patients with systemic sclerosis.
    Yanaba K; Muroi E; Yoshizaki A; Hara T; Ogawa F; Shimizu K; Yozaki M; Hasegawa M; Fujimoto M; Takehara K; Sato S
    J Rheumatol; 2009 Sep; 36(9):1917-23. PubMed ID: 19605674
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The -670G>A polymorphism in the FAS gene promoter region influences the susceptibility to systemic sclerosis.
    Liakouli V; Manetti M; Pacini A; Tolusso B; Fatini C; Toscano A; Cipriani P; Guiducci S; Bazzichi L; Codullo V; Ruocco L; Dell'orso L; Carubbi F; Marrelli A; Abbate R; Bombardieri S; Ferraccioli G; Montecucco C; Valentini G; Matucci-Cerinic M; Ibba-Manneschi L; Giacomelli R
    Ann Rheum Dis; 2009 Apr; 68(4):584-90. PubMed ID: 18445624
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low versus high-dose iloprost therapy over 21 days in patients with secondary Raynaud's phenomenon and systemic sclerosis: a randomized, open, single-center study.
    Kawald A; Burmester GR; Huscher D; Sunderkötter C; Riemekasten G
    J Rheumatol; 2008 Sep; 35(9):1830-7. PubMed ID: 18634152
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased apoptosis of peripheral blood mononuclear cells in patients with perennial allergic asthma/rhinitis: relation to serum markers of apoptosis.
    Grzegorczyk J; Kowalski ML; Pilat A; Iwaszkiewicz J
    Mediators Inflamm; 2002 Aug; 11(4):225-33. PubMed ID: 12396474
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum soluble Fas levels in patients with autoimmune rheumatic diseases.
    Sahin M; Aydintug O; Tunc SE; Tutkak H; Naziroğlu M
    Clin Biochem; 2007 Jan; 40(1-2):6-10. PubMed ID: 17056024
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuron specific enolase concentration is increased in serum and decreased in platelets of patients with active systemic sclerosis.
    Massabki PS; Silva NP; Lourenço DM; Andrade LE
    J Rheumatol; 2003 Dec; 30(12):2606-12. PubMed ID: 14719201
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Raynaud's phenomenon and plasma endothelin: correlations with capillaroscopic patterns in systemic sclerosis.
    Sulli A; Soldano S; Pizzorni C; Montagna P; Secchi ME; Villaggio B; Seriolo B; Brizzolara R; Cutolo M
    J Rheumatol; 2009 Jun; 36(6):1235-9. PubMed ID: 19369451
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elevated serum BAFF levels in patients with systemic sclerosis: enhanced BAFF signaling in systemic sclerosis B lymphocytes.
    Matsushita T; Hasegawa M; Yanaba K; Kodera M; Takehara K; Sato S
    Arthritis Rheum; 2006 Jan; 54(1):192-201. PubMed ID: 16385515
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor-associated antigens in systemic sclerosis and systemic lupus erythematosus: associations with organ manifestations, immunolaboratory markers and disease activity indices.
    Szekanecz E; Szucs G; Szekanecz Z; Tarr T; Antal-Szalmás P; Szamosi S; Szántó J; Kiss E
    J Autoimmun; 2008 Dec; 31(4):372-6. PubMed ID: 18926664
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elevated serum APRIL levels in patients with systemic sclerosis: distinct profiles of systemic sclerosis categorized by APRIL and BAFF.
    Matsushita T; Fujimoto M; Hasegawa M; Tanaka C; Kumada S; Ogawa F; Takehara K; Sato S
    J Rheumatol; 2007 Oct; 34(10):2056-62. PubMed ID: 17896803
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The levels of serum-soluble Fas in patients with rheumatoid arthritis and systemic sclerosis.
    Ateş A; Kinikli G; Turgay M; Duman M
    Clin Rheumatol; 2004 Oct; 23(5):421-5. PubMed ID: 15459814
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prolactin and thyroid hormones in patients with systemic sclerosis: correlations with disease manifestations and activity.
    Shahin AA; Abdoh S; Abdelrazik M
    Z Rheumatol; 2002 Dec; 61(6):703-9. PubMed ID: 12491136
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.